Ilyang Pharm (007570) — Capital Reinvestment Ratio
Latest as of June 2025:
1.47x
Ilyang Pharm (007570) has a Capital Reinvestment Ratio of 1.47x as of June 2025, meaning it reinvests 1% of its operating cash flow (₩2.26 Billion) in capital expenditures (₩3.32 Billion). See Ilyang Pharm free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
1.47x
Capex / Operating Cash Flow
Operating Cash Flow
₩2.26 Billion
KRW
Capital Expenditures
₩3.32 Billion
KRW
Data as of
Jun 2025
Most recent filing
Ilyang Pharm Capital Reinvestment Ratio (2003–2024)
This chart tracks Ilyang Pharm's Capital Reinvestment Ratio across 12 annual periods.
Annual Capital Reinvestment Ratio for Ilyang Pharm (2003–2024)
Year-by-year Capital Reinvestment Ratio for Ilyang Pharm from 2003 to 2024. For live market cap and broader valuation context, see 007570 stock market capitalisation.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 7.23x | ₩5.61 Billion | ₩40.62 Billion | ▲ +1391.3% |
| 2023 | 0.49x | ₩13.34 Billion | ₩6.47 Billion | ▲ +255.8% |
| 2022 | 0.14x | ₩29.94 Billion | ₩4.08 Billion | ▼ -29.2% |
| 2021 | 0.19x | ₩67.02 Billion | ₩12.91 Billion | ▲ +8.8% |
| 2020 | 0.18x | ₩57.48 Billion | ₩10.17 Billion | ▲ +194.7% |
| 2019 | 0.06x | ₩36.19 Billion | ₩2.17 Billion | ▼ -14.1% |
| 2018 | 0.07x | ₩22.12 Billion | ₩1.55 Billion | ▼ -44.5% |
| 2017 | 0.13x | ₩30.03 Billion | ₩3.78 Billion | ▼ -67.0% |
| 2016 | 0.38x | ₩26.98 Billion | ₩10.31 Billion | ▼ -4.3% |
| 2015 | 0.40x | ₩40.27 Billion | ₩16.07 Billion | ▼ -46.5% |
| 2014 | 0.75x | ₩18.63 Billion | ₩13.89 Billion | ▲ +1710.6% |
| 2003 | 0.04x | ₩10.08 Billion | ₩415.11 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow